Complement as a target in COVID-19?

Antonio M Risitano, Dimitrios C Mastellos, Markus Huber-Lang, Despina Yancopoulou, Cecilia Garlanda, Fabio Ciceri, John D Lambris, Antonio M Risitano, Dimitrios C Mastellos, Markus Huber-Lang, Despina Yancopoulou, Cecilia Garlanda, Fabio Ciceri, John D Lambris

Abstract

There is an urgent need to develop effective therapies for COVID-19. Here, we urge immunologists and clinicians to consider the potential of targeting the complement system in these patients.

Conflict of interest statement

J.D.L. is the founder of Amyndas Pharmaceuticals and inventor of patents related to complement inhibitors, including a technology licensed to Apellis Pharmaceuticals. A.M.R. has received support from or served as an adviser for Biocryst, Achillion, Alexion, Alnylam, Amyndas, Apellis, Novartis, Roche, Omeros, Pfizer, Rapharma, Samsung and Sanofi. M.H.-L. holds a patent relating to C5a inhibition licensed to InflaRx. D.Y. is the Managing Director of Amyndas Pharmaceuticals. D.C.M., C.G. and F.C. declare no competing interests.

Figures

Fig. 1. Targeting complement in SARS-CoV-2-associated lung…
Fig. 1. Targeting complement in SARS-CoV-2-associated lung injury.
Complement activation may contribute to the maladaptive inflammatory response seen in some patients with severe COVID-19. Inhibition of C3 or C5 may have therapeutic potential. ARDS, acute respiratory distress syndrome.

References

    1. Guan W-j, et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2002032.
    1. Li G, et al. Coronavirus infections and immune responses. J. Med. Virol. 2020;92:424–432. doi: 10.1002/jmv.25685.
    1. Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nat. Rev. Drug Discov. 2018;18:707–729. doi: 10.1038/s41573-019-0031-6.
    1. Gralinski LE, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio. 2018 doi: 10.1128/mBio.01753-18.
    1. Zilow G, et al. Generation of anaphylatoxin C3a in plasma and bronchoalveolar lavage fluid in trauma patients at risk for the adult respiratory distress syndrome. Crit. Care Med. 1992;20:468–473. doi: 10.1097/00003246-199204000-00006.
    1. Gao T, et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. medRxiv. 2020 doi: 10.1101/2020.03.29.20041962.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa